Context Therapeutics Inc.
CNTX Nasdaq
SEC CIK 1842952
Follow Context Therapeutics
Weekly email: filings, results
Net income
−$7.6M
+21.4% vs same quarter last year
EPS, diluted
−$0.08
+20% vs same quarter last year
Operating cash flow
−$6.6M
−0% vs same quarter last year
Operating income
−$8M
+25% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$36.1M |
| FY24 | −$26.7M |
| FY23 | −$24M |
| FY22 | −$14.8M |
| FY21 | −$10.5M |
| FY20 | - |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$26.4M |
| FY24 | −$14.6M |
| FY23 | −$21M |
| FY22 | −$13.6M |
| FY21 | −$8.8M |
| FY20 | - |
| FY19 | - |